Drug Profile
Research programme: IPL99 series - Inflazyme
Alternative Names: IPL99 series research programme - InflazymeLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in Canada
- 26 Feb 2004 This programme is still in active development - 2nd Annual BioPartnering North America conference (BPN-2004)
- 27 Feb 2003 The IPL99 programme is available for partnering (http://www.inflazyme.com)